Associations of Tumor Necrosis Factor G-308A with Childhood Asthma and Wheezing

Yu-Fen Li, PhD, MPH, W. James Gauderman, PhD, Ed Avol, MS, Louis Dubeau, MD, PhD, and Frank D. Gilliland, MD, PhD

ONLINE DATA SUPPLEMENT

Table E1. Characteristics of CHS participants, with and without TNF genotyping results.

	With TNF	With TNF genotyped		Without TNF genotyped	
	n	%	n	%	
Total = 625	9 3699	59.1%	2560	40.9%	
Demographic information					
Gender					
Girls	1978	53.5%	1267	49.5%	
Boys	1721	46.5%	1293	50.5%	
Age at study entry					
8-9	1939	52.5%	966	37.7%	
10-11	787	21.3%	561	21.9%	
12-13	552	14.9%	449	17.5%	
14-18	421	11.3%	584	22.8%	
Ethnicity					
Non-Hispanic Whites	2182	59.0%	1243	48.6%	
Hispanics	989	26.7%	784	30.6%	
African Americans	156	4.2%	178	6.9%	
Asians	157	4.2%	132	5.2%	
Others	215	5.8%	223	8.7%	
Gestational Age					
Full term	3189	86.2%	2191	85.6%	
< 4 weeks early	254	6.9%	144	5.6%	
\geq 4 weeks early	160	4.3%	79	3.1%	
Missing	99	2.7%	146	5.7%	
<i>In utero</i> exposure to maternal smoking					
Yes	603	16.9%	527	22.0%	
Any lifetime SHS exposure					
Yes	1230	34.6%	1134	47.6%	
Current SHS exposure					
Yes	650	18.1%	716	29.7%	
Ozone exposure					
High (≥ 50 ppb)	2166	58.6%	1535	60.0%	
Lifetime residence					
Yes	1271	34.4%	815	31.8%	
Respiratory Outcomes	, -	2, 0	010	21.070	
Ever asthma	551	15.2%	319	13.1%	
Ever wheezing	1222	34.8%	738	31.3%	
Current wheezing*	704	23.6%	429	21.0%	
Medication for wheezing*	401	14.9%	238	12.8%	

SHS = second-hand smoke
* based on self-report for the past 12 months

Table E2. Primer and Probe Sequences for TNF, GSTM1 and GSTP1 A105G Variants

GENE		Sequences
TNF	Forward primer	5'-GAAATGGAGGCAATAGGTTTTGA-3'
	Reverse primer	5'-GTAGGACCCTGGAGGCTGAAC-3'
	Probe for G allele	5'-(6FAM)CCGTCCCCATGCC-3'
	Probe for A allele	5'-(VIC)-CCGTCCTCATGCC3'
GSTM1	Forward primer	5'-TGGAACCTCCATAACACGTGA-3'
	Reverse primer	5'-TGGAAACTTCTGCAAACTCAGC-3'
	Probe	5'-(6FAM)AAGCGGCCATGGTTTGCAGG-3'
GSTP1	Forward primer	5'-CCTGGTGGACATGGTGAATG-3'
	Reverse primer	5'-TGCTCACATAGTTGGTGTAGATGA-3'
	Probe for A allele	5'-(6FAM)TGCAAATACATCTCCCT-3'
	Probe for G allele	5'-(VIC)CTGCAAATACGTCTCC-3'

Table E3. Associations of TNF G-308A with Asthma and Wheezing Outcomes in Children at CHS entry, odds ratio (OR) and 95% confidence interval (CI) in two cohorts of 4^{th} graders

		Coho	ort 1 entered	Coho	ort 2 entered
Outcomes	TNF	in 1993		in 1996	
	<u>-</u>	OR	95% CI	OR	95% CI
Ever asthma	GA/AA	1.0		1.0	
	GG	0.8	(0.6, 1.0)	0.8	(0.6, 1.2)
Ever wheezing	GA/AA	1.0		1.0	
_	GG	0.8	(0.7, 1.0)	0.7	(0.6, 0.9)
Current wheezing	GA/AA	1.0		1.0	
-	GG	0.7	(0.6, 0.9)	0.7	(0.5, 0.9)
Medication for wheezing	GA/AA	1.0		1.0	
	GG	0.7	(0.5, 0.9)	0.6	(0.3, 0.8)

Models are adjusted for age, sex, race/ethnicity, town, lifetime residence, grade, and smoking exposure (*in utero* and second-hand)

Table E4. The association of TNF G-308A with asthma and wheezing outcomes in 4th-grade CHS participants in lower and higher ozone communities * , odds ratio (OR) and 95% confidence interval (CI) in two cohorts of 4^{th} graders

	_	Cohort 1entered in 1993				
Outcomes	TNF	Low ozone		High ozone		
	_	OR	95% CI	OR	95% CI	
Ever asthma	GA/AA	1.0		1.0		
	GG	0.8	(0.4, 1.5)	0.9	(0.6, 1.4)	
Ever wheezing	GA/AA	1.0		1.0		
	GG	0.6	(0.4, 0.9)	1.0	(0.7, 1.5)	
Current wheezing	GA/AA	1.0		1.0		
-	GG	0.6	(0.4, 1.1)	0.9	(0.6, 1.4)	
Medication for wheezing	GA/AA	1.0		1.0		
	GG	0.6	(0.3, 1.2)	0.8	(0.5, 1.4)	

		Cohort 2 entered in 1996			
Outcomes	TNF	Low ozone		High ozone	
		OR	95% CI	OR	95% CI
Ever asthma	GA/AA	1.0		1.0	
	GG	0.7	(0.4, 1.3)	0.9	(0.6, 1.5)
Ever wheezing	GA/AA	1.0		1.0	
-	GG	0.5	(0.4, 0.8)	0.9	(0.7, 1.3)
Current wheezing	GA/AA	1.0		1.0	
-	GG	0.5	(0.3, 0.8)	0.9	(0.6, 1.3)
Medication for wheezing	GA/AA	1.0		1.0	
	GG	0.3	(0.2, 0.6)	0.9	(0.5, 1.5)

Models are adjusted for age, sex, race/ethnicity, town, lifetime residence, grade, and smoking exposure (*in utero* and second-hand)

Table E5. Associations of GSTM1 and GSTP1 with Wheezing Outcomes in 4th-grade CHS Children, odds ratio (OR) and 95% confidence interval (CI)

Outcomes	GSTM1	(ref=present)	GSTP1 (ref=Ile/Ile)		
Outcomes	OR	95% CI	OR	95% CI	
Ever wheezing	1.0		1.0		
	0.9	(0.8, 1.1)	1.0	(0.9, 1.2)	
Current wheezing	1.0		1.0		
	1.0	(0.8, 1.2)	1.1	(0.9, 1.3)	
Medication for wheezing	1.0		1.0		
	0.9	(0.7, 1.3)	1.1	(0.9, 1.5)	

Models are adjusted for age, sex, race/ethnicity, town, lifetime residence, grade, and smoking exposure (*in utero* and second-hand)